These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2918505)

  • 21. Antinociceptive effects of neuropeptide Y and related peptides in mice.
    Broqua P; Wettstein JG; Rocher MN; Gauthier-Martin B; Riviere PJ; Junien JL; Dahl SG
    Brain Res; 1996 Jun; 724(1):25-32. PubMed ID: 8816252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural study of the N-terminal segment of neuropeptide tyrosine.
    Forest M; Martel JC; St-Pierre S; Quirion R; Fournier A
    J Med Chem; 1990 Jun; 33(6):1615-9. PubMed ID: 2342055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-helical small molecular size analogues of neuropeptide Y: structure-activity relationships.
    Jung G; Beck-Sickinger AG; Dürr H; Gaida W; Schnorrenberg G
    Biopolymers; 1991 May; 31(6):613-9. PubMed ID: 1657233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypotensive effects of [D-Tyr27,36, D-Thr32]Neuropeptide Y (27-36).
    Roscoe AK; Leach SM; Nyce JW; Wooles WR
    Peptides; 1995; 16(8):1411-5. PubMed ID: 8745051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-alpha-biotinylated-neuropeptide Y analogs: syntheses, cardiovascular properties, and application to cardiac NPY receptor visualization.
    Balasubramaniam A; Sheriff S; Ferguson DG; Stein M; Rigel DF
    Peptides; 1990; 11(6):1151-6. PubMed ID: 1965029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of various neuropeptide Y/peptide YY fragments on electrically-evoked contractions of the rat vas deferens.
    Grundemar L; Håkanson R
    Br J Pharmacol; 1990 May; 100(1):190-2. PubMed ID: 2372659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y.
    Bischoff A; Avramidis P; Erdbrügger W; Münter K; Michel MC
    Br J Pharmacol; 1997 Apr; 120(7):1335-43. PubMed ID: 9105710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on Y1, Y2 and Y3 receptor sub-types.
    Dumont Y; Satoh H; Cadieux A; Taoudi-Benchekroun M; Pheng LH; St-Pierre S; Fournier A; Quirion R
    Eur J Pharmacol; 1993 Jul; 238(1):37-45. PubMed ID: 8405081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.
    Kirby DA; Koerber SC; May JM; Hagaman C; Cullen MJ; Pelleymounter MA; Rivier JE
    J Med Chem; 1995 Oct; 38(22):4579-86. PubMed ID: 7473586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo structure activity study supports the existence of heterogeneous neuropeptide Y receptors.
    Jolicoeur FB; Michaud JN; Menard D; Fournier A
    Brain Res Bull; 1991 Feb; 26(2):309-11. PubMed ID: 2012991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanotropin release inhibiting activity of neuropeptide Y: structure-activity relationships.
    Danger JM; Tonon MC; Lamacz M; Martel JC; Saint-Pierre S; Pelletier G; Vaudry H
    Life Sci; 1987 May; 40(19):1875-80. PubMed ID: 3573984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre- and postjunctional actions of neuropeptide Y and related peptides.
    Potter EK; Mitchell L; McCloskey MJ; Tseng A; Goodman AE; Shine J; McCloskey DI
    Regul Pept; 1989 May; 25(2):167-77. PubMed ID: 2756153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of neuropeptide Y and its fragments upon basal and electrically stimulated ion secretion in rat jejunum mucosa.
    Cox HM; Cuthbert AW
    Br J Pharmacol; 1990 Oct; 101(2):247-52. PubMed ID: 2257432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
    Iyengar S; Li DL; Simmons RM
    J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiovascular actions of centrally administered neuropeptide Y.
    Scott NA; Webb V; Boublik JH; Rivier J; Brown MR
    Regul Pept; 1989 May; 25(2):247-58. PubMed ID: 2756158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of centrally truncated analogues of neuropeptide Y at Y1 and Y2 receptor subtypes in vivo.
    McCloskey MJ; Moriarty MJ; Tseng A; Shine J; Potter EK
    Neuropeptides; 1997 Apr; 31(2):193-7. PubMed ID: 9179873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of the Y-1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats.
    Kalra SP; Fuentes M; Fournier A; Parker SL; Crowley WR
    Endocrinology; 1992 Jun; 130(6):3323-30. PubMed ID: 1317781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropeptide Y N-terminal deletion fragments: correlation between solution structure and receptor binding activity at Y1 receptors in rat brain cortex.
    Hu L; Balse P; Doughty MB
    J Med Chem; 1994 Oct; 37(21):3622-9. PubMed ID: 7932589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes.
    Grundemar L; Krstenansky JL; Håkanson R
    Eur J Pharmacol; 1993 Mar; 232(2-3):271-8. PubMed ID: 8467862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat.
    Aguirre JA; Fuxe K; Agnati LF; von Euler G
    Neurosci Lett; 1990 Oct; 118(1):5-8. PubMed ID: 2259468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.